ALX Oncology Holdings Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
ALX Oncology Holdings Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue0.000.000.000.001.18
Cost of Revenue0.870.000.000.001.08
Gross Profit-0.870.000.000.000.11
Operating Expenses
Research & Development116.37141.8098.4060.1728.96
Selling, General & Administrative26.0928.4829.0423.3914.81
Operating Expenses142.47170.28127.4483.5644.85
Operating Income-142.47-170.28-127.44-83.56-43.66
Other Income/Expense
Interest Income9.3710.654.280.090.12
Interest Expense-1.731.570.24-0.010.00
Other Income/Expense-0.02-0.39-0.02-0.011.03
Income
Income Before Tax-134.85-160.81-123.42-83.48-45.50
Income Tax Expense0.00-1.480.06-0.020.24
Net Income-134.85-160.81-123.48-83.46-45.74
Net Income - Continuous Operations-134.85-160.81-123.48-83.460.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-141.60-158.36-122.84-83.50-43.46
EBIT-142.47-160.72-123.18-83.56-43.66
Depreciation & Amortization0.870.800.340.050.20
Earnings Per Share
Basic EPS-3.00-4.00-3.00-2.00-3.00
Diluted EPS-3.00-4.00-3.00-2.00-3.00
Basic Shares Outstanding52.1742.9940.7040.3118.49
Diluted Shares Outstanding52.1742.9940.7040.3118.49